The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
Open accessAbstract
CONTEXT: The standard criteria used to evaluate tumor response, the Response Evaluation Criteria in Solid Tumors (RECIST), were developed to assess tumor shrinkage after cytotoxic chemotherapy and may be limited in assessing response to biologic agents, which have a cytostatic mechanism of action. OBJECTIVE: To validate novel tumor response criteria based on morphologic changes observed on computed tomography (CT) in patients with colorectal liver metastases treated with bevacizumab-containing chemotherapy regimens. DESIGN, SETTING, AND PATIENTS: A total of 234 colorectal liver metastases were analyzed from 50 patients who underwent hepatic resection after preoperative chemotherapy that included bevacizumab at a comprehensive US cancer center from 2004 to 2007; date of last follow-up was March 2008. All patients underwent routine contrast-enhanced CT at the start and end of preoperative therapy. Three blinded, independent radiologists evaluated images for morphologic response, based on metastases changing from heterogeneous masses with ill-defined margins into homogeneous hypoattenuating lesions with sharp borders. These criteria were validated with a separate cohort of 82 patients with unresectable colorectal liver metastases treated with bevacizumab-containing chemotherapy. MAIN OUTCOME MEASURES: Response determined using morphologic criteria and RECIST was correlated with pathologic response in resected liver specimens and with patient survival. RESULTS: Interobserver agreement for scoring morphologic changes was good among 3 radiologists (kappa, 0.68-0.78; 95% confidence interval [CI], 0.51-0.93). In resected tumor specimens, the median (interquartile range [IQR]) percentages of residual tumor cells for optimal morphologic response was 20% (10%-30%); for incomplete response, 50% (30%-60%); and no response, 70% (60%-70%; P < .001). With RECIST, the median (IQR) percentages of residual tumor cells were for partial response 30% (10%-60%); for stable disease, 50% (20%-70%); and for progressive disease, 70% (65%-70%; P = .04). Among patients who underwent hepatic resection, median overall survival was not yet reached with optimal morphologic response and 25 months (95% CI, 20.2-29.8 months) with incomplete or no morphologic response (P = .03). In the validation cohort, patients with optimal morphologic response had median overall survival of 31 months (95% CI, 26.8-35.2 months) compared with 19 months (95% CI, 14.6-23.4 months) with incomplete or no morphologic response (P = .009). RECIST did not correlate with survival in either the surgical or validation cohort. CONCLUSION: Among patients with colorectal liver metastases treated with bevacizumab-containing chemotherapy, CT-based morphologic criteria had a statistically significant association with pathologic response and overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
Adam, R., Pascal, G., Castaing, D., Azoulay, D., Delvart, V., Paule, B., Levi, F., & Bismuth, H. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000145964.08365.01 · Cited by 1,001
Blazer, D. G., Kishi, Y., Maru, D. M., Kopetz, S., Chun, Y. S., Overman, M. J., Fogelman, D., Eng, C., Chang, D. Z., Wang, H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5299 · Cited by 604
Self-citationRubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A. D., Andres, A., Audard, V., Sartoretti, P., Dousset, B., Majno, P. E., Soubrane, O., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl386 · Cited by 523
Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., Chang, D. Z., Curley, S. A., Abdalla, E. K., Ellis, L. M., et al. (2007) · Cancer · doi:10.1002/cncr.23099 · Cited by 375
Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Charnsangavej, C., Clary, B., Fong, Y., Grothey, A., Pawlik, T. M., & Choti, M. A. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9023-y · Cited by 354
Adam, R., Wicherts, D. A., de Haas, R. J., Aloia, T., Lévi, F., Paule, B., Guettier, C., Kunstlinger, F., Delvart, V., Azoulay, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7471 · Cited by 300
Ajani, J. A., Mansfield, P. F., Crane, C. H., Wu, T. T., Lunagomez, S., Lynch, P. M., Janjan, N., Feig, B., Faust, J., Yao, J. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.305 · Cited by 282
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 261
Grothey, A., Hedrick, E. E., Mass, R. D., Sarkar, S., Suzuki, S., Ramanathan, R. K., Hurwitz, H. I., Goldberg, R. M., & Sargent, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8099 · Cited by 171
Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model
Kan, Z., Phongkitkarun, S., Kobayashi, S., Tang, Y., Ellis, L. M., Lee, T., & Charnsangavej, C. (2005) · Radiology · doi:10.1148/radiol.2363041293 · Cited by 122
Hepatic colorectal metastases: correlation of MR imaging and pathologic appearance.
Outwater, E. K., Tomaszewski, J. E., DALY, J. M., & Kressel, H. Y. (1991) · Radiology · doi:10.1148/radiology.180.2.2068294 · Cited by 116
Imaging of Angiogenesis: Clinical Techniques and Novel Imaging Methods
Provenzale, J. M. (2006) · American Journal of Roentgenology · doi:10.2214/ajr.06.0280 · Cited by 88
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Adam, R., De Gramont, A., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0121 · Cited by 583
Tsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z.-H., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 454
Metadata
- Authors
- Chun, Y. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-02
- Volume
- 302
- Issue
- 21
- Pages
- 2338
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2151062573
- Cited by
- 501
- References
- 16
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.